DTI in Children With Multiple Sclerosis

NCT ID: NCT02361697

Last Updated: 2016-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging (DTI) by magnetic resonance imaging (MRI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In children and adolescents with either multiple sclerosis or clinically isolated syndrome an MRI with special DTI-sequences of the brain is performed at timepoint of first manifestation of disease and every 6 months at 3 Tesla MRI according to a specific investigation protocol.

Besides MRI-DTI several clinical data are recorded every 6 months:

1. expanded disability status scale (EDSS)
2. disease activity/ relapse rate
3. lesion load (number of T2-lesions)
4. brain atrophy
5. visual and somatosensoric evoked potentials (VEP, SSEP)
6. neuropsychological examination

Furthermore a complete neurological examination is done every 6 months and particular medication of each patient is recorded in a specific investigator form (case report form, CRF)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis - Relapsing Remitting Clinically Isolated Syndrome, CNS Demyelinating

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DTI-MRI

MRI of the brain with specific DTI-sequences according to a specific investigation protocol

Group Type OTHER

DTI-MRI

Intervention Type OTHER

MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DTI-MRI

MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* informed consent
* diagnosis of multiple sclerosis (MS) according to the McDonald criteria 2010 and the consensus recommendations of International Pediatric MS Study Group (IPMSSG) (Krupp et al 2013)
* diagnosis of CIS according to the consensus recommendation of IPMSSG (Krupp et al 2013)
* all types of medication/therapy

Exclusion Criteria

* pregnancy
* claustrophobia
* allergic reaction of gadolinium (contrast medium)
* implantation of cardiac device
* implantation of neurostimulators
* implantation of cochlea implants
* presence of tattooing (over 20% of body surface)
* presence of permanent-make-up
* presence of permanent transdermal patches
* presence of special catheter systems with temperature probes which cannot be removed
* implantation of metalliferous implants or implants which could contain metal traces
* implantation of artificial heart valves
* implantation of stents or coils
* presence of metal fragments in the eyes
Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Muenster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christiane Elpers, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Muenster

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Muenster

Münster, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christiane Elpers, MD

Role: CONTACT

0049 251 47774

Gerhard Kurlemann, MD

Role: CONTACT

0049 251 47762

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christiane Elpers, MD

Role: primary

0049 251 47774

Gerhard Kurlemann, MD

Role: backup

0049 251 47762

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-490-f-S

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.